Abstract: The present invention relates to the use of nutritional compositions comprising non-digestible oligosaccharides for preventing corticoid administration, particularly to infants.

Abstract: The present invention concerns the use of uronic acid saccharide for preventing growth of Enterobacter sakazakii.

Abstract: Provided is a pharmaceutical or dietetic product, which serves for reducing and/or blocking the adhesion of pathogenic substances and organisms to eucaryontic cells, in particular mammal cells. Said preparation contains at least one carbohydrate having an uronic acid unit on one of the ends thereof. 10 to 100% of the present, terminal uronic acid units pertaining to the carbohydrates are provided with a double bond that is especially situated between the C4 and C5 atom.

Abstract: Nutritional compositions with health benefits comprising bacterial strains and galactooligosaccharides are disclosed.

Abstract: Neutral straight-chain or branched oligosaccharides for preventing the invasion and infection of mammal cells by pathogens and for fighting diseases caused by such pathogens are disclosed. Food, dietetic products and pharmaceutical agents containing oligosaccharides consist of a base unit of formula (I), and between 0 and 19 other units of formula (II), which are linked directly or indirectly to the base unit. Gal represents a galactose monosaccharide unit; Glc represents a glucose monosaccharide unit; HexNAc rpresents an N-acetylated galactosamine or glucosamine monosaccharide unit (GalNAc or GlcNAc); R independently represent a ? 1-3 or ? 1-6 glycosidic link to HexNAc monosaccharide of the next [Gal-HexNAc] unit (II), and on a terminal [Gal-HexNAc] unit, or R are not present; and a terminal [Gal-HexNAc] unit, wherein R represent a deoxyhexose radical, can have another deoxyhexose radical on the HexNAc monosaccharide unit.

Abstract: The present invention relates to a method and a composition for feeding low birthweight infants (LBW infants), very low birthweight infants (VLBW infants), extremely low birthweight infants (ELBW infants) and preterm infants for improving oral tolerance.

Abstract: Cereal-based semi-liquid and/or semi-solid compositions suitable for supporting the transition period wherein the infant changes from a diet consisting of breast milk or liquid infant formula to solid adult foods, comprising uronic acid carbohydrates with a degree of polymerisation (DP) between 10 and 300 and also uses thereof are disclosed.

Abstract: Provided is a pharmaceutical or dietetic product, which serves for reducing and/or blocking the adhesion of pathogenic substances and organisms to eucaryontic cells, in particular mammal cells. Said preparation contains at least one carbohydrate having an uronic acid unit on one of the ends thereof. 10 to 100% of the present, terminal uronic acid units pertaining to the carbohydrates are provided with a double bond that is especially situated between the C4 and C5 atom.

Abstract: The invention concerns a method for stimulating intestinal barrier integrity in a patient infected with HIV by administering to said patient composition comprising: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA), and at least two distinct oligosaccharides.

Abstract: A nutritional or pharmaceutical composition containing a fat component, a protein component and a carbohydrate component and comprising whey and casein. The composition has a weight ratio of casein to whey is 1:1 to 1:2.4 and that the composition contains: a) at least 3 grams arginine per 100 grams protein; b) at least 10 wt. % linoleic acid based on total fatty acids; c) at least 1 wt. % alpha linolenic acid based on total fatty acids; d) at least one long chain-polyunsaturated fatty acid in an amount exceeding 0.1 wt. % based on total fatty acids. The long chain polyunsaturated fatty acid being docosahexaenoic acid, arachidonic acid and eicosapentaenoic acid; e) 5 to 25 wt. % of at least one polyunsaturated fatty acid based on total fatty acids; and f) 2 to 12 grams indigestible oligosaccharides having a degree of polymerisation of 2 to 100 per 100 gram dry weight of the composition. The composition reduces—among others—the risks attached to feeding whey dominant infant formula.

Abstract: The present invention concerns a therapy aimed at language and/or social skills in infants through administration of components stimulating the development of a healthy intestinal flora.

Abstract: The present invention relates to methods and nutritional compositions for stimulating the immune system, particularly in subjects with an impaired immune system such as 5 infants, said method comprising administering a composition comprising sheep milk and/or short chain oligosaccharides.

Abstract: The invention relates to novel enzymes, which transfer sialic acid from a donor molecule onto an acceptor molecule (trans-sialidases). The enzymes are isolated from the protozoan Trypanosoma congolense.

Abstract: A carbohydrate mixture for dietetic foods and pharmaceuticals containing several carbohydrates is provided according to the present invention. Said carbohydrate mixture is characterized in that they contain or consist of two different, substantially soluble carbohydrate components A and B, which remain undigested in the gastrointestinal tract and enter the large intestine without being resorbed, that said carbohydrate component A is composed of at least one monosaccharide or of at least one oligosaccharide (disaccharide to hexasaccharide) or of a mixture of two or more of these saccharides, that the carbohydrate component B is composed of a polysaccharide (from heptasaccharide onwards) or of a mixture of two or more polysaccharides, that the carbohydrate component A=5 to 95 wt-% and the carbohydrate component B=5 to 95 wt-% of the sum of the carbohydrate components A+B (=100 wt-%), and that at least 80 wt-% of the carbohydrates/saccharides of the carbohydrate components A and B have a prebiotic effect.

Abstract: The present invention provides processes for the manufacture of uronic acid oligosaccharides using extrusion. The uronic acid polymers are extruded with an enzyme, under basic conditions (pH>9) and/or under high shear.

Abstract: A food or supplement for pregnant women comprising water soluble, non-digestible saccharides is described. The composition is used to improve the flora and/or immune system of the pregnant women, to improve the immune system of the infant and to improve the intestinal flora of the infant after birth.

Abstract: A carbohydrate mixture for dietetic foods and pharmaceuticals containing several carbohydrates is provided. The carbohydrate mixture comprises two different, substantially soluble carbohydrate components A and B, which remain undigested in the gastrointestinal tract and enter the large intestine without being resorbed. Component A comprises at least one monosaccharide, at least one oligosaccharide (disaccharide to hexasaccharide), or a mixture thereof. Component B comprises a polysaccharide or a mixture of two or more polysaccharides. Component A constitutes 5 to 95 wt-% and Component B constitutes 5 to 95 wt-% of the sum of the Components; and at least 80 wt-% of the carbohydrates/saccharides of Components A and B have a prebiotic effect. The inventive carbohydrate mixture exhibits not only a nutritive effect, but also stimulates health-promoting microorganisms present in the natural flora of the large intestine.

Abstract: The present invention provides the use of a composition comprising non-digestible oligosaccharide for the manufacture of a composition for enteral administration to an infant delivered via caesarean section.

Abstract: The present invention provides the use of a composition comprising uronic acid oligosaccharide for the manufacture of a composition for enteral administration to an infant delivered via caesarean section.

Abstract: The present invention relates to methods for feeding and to compositions to be administered to infants delivered via caesarian section and in particular to the use of a) at least two different microorganisms; or b) at least one microorganism and at least one indigestible oligosaccharide; or c) at least two different Bifidobacteria species, subspecies or strains for the manufacture of a composition for enteral administration to an infant delivered via caesarean section. Thereby it is possible to stimulate the healthy development of the intestinal flora of said infants.